✉news HealthMedicine first seen 2 d ago, last 2 d ago, peak #29
WGS Oncodetect beats WES version in colorectal cancer recurrence detection
Original: WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer, company reports
Guardant Health reports that its whole-genome sequencing version of the Oncodetect molecular residual disease test detected cancer recurrence with higher sensitivity than the whole-exome sequencing version in colorectal cancer. The company says the findings support the WGS-based assay's ability to identify minimal residual disease earlier, which could matter for monitoring patients after treatment and guiding follow-up decisions in colorectal cancer care.
Why now: The company announced comparative performance data for its cancer recurrence detection test, drawing attention from oncology observers.
OncodetectGuardant Healthcolorectal cancer
Rank over time, top of the chart is #1. 3 snapshots from 2 d ago to 2 d ago.
Evidence
- WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer, company reports · 2 Minute Medicine
API: https://socialmediatrends-api.osmike.com/v1/trends/3815463